How does the BFAST clinical trial work? This clinical trial is recruiting people who have a specific type of lung cancer called ‘non­-small cell lung cancer’ or NSCLC, which cannot be surgically removed (inoperable). Changes in genetic material, known as mutations, can cause cancer.

BFAST is the first trial to use blood-based NGS prospectively as the sole method of identifying patients with NSCLC with an actionable genetic alteration.

Oct 23, 2024 · On first glance it might seem that Roche is losing faith in its KRAS G12C inhibitor – the company disclosed on Wednesday that it had discontinued the divarasib cohort of its phase 2/3 B-Fast study in second-line NSCLC.

Introduction: The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively evaluating the relationship between blood-based next-generation sequencing (NGS) detection of actionable genetic alterations and activity of targeted therapies or immunotherapy in treatment-naive advanced or metastatic NSCLC.

Jun 19, 2024 · Nature Medicine - Results from this single-arm cohort of the BFAST trial showed that the clinical efficacy of entrectinib in patients with ROS1-positive NSCLC, selected using liquid biopsies,...

Aug 22, 2022 · BFAST (NCT03178552)—an open-label, global, multicohort trial—evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV...

Introduction: The Blood First Assay Screening Trial is an ongoing open-label, multicohort study, prospectively eval-uating the relationship between blood-based next-genera-tion sequencing (NGS) detection of actionable genetic alterations and activity of targeted therapies or immuno-therapy in treatment-naive advanced or metastatic NSCLC.

Dec 1, 2021 · BFAST is the first trial to use blood-based NGS prospectively as the sole method of identifying patients with NSCLC with an actionable genetic alteration.

BFAST (NCT03178552)-an open-label, global, multicohort trial-evaluated the safety and efficacy of first-line targeted therapies or immunotherapy in patients with unresectable Stage IIIB or IV advanced or metastatic non-small cell lung cancer who were selected for biomarker status using blood-based targeted next-generation sequencing. In the ...

BFAST is a screening and interventional umbrella trial for pts selected based on bTMB or somatic mutations. Eligible pts must have previously untreated, stage IIIB-IVB NSCLC of any histology and measurable disease per RECIST v1.1.